Sunitinib: 9 agencies, 2006–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 18.9 years separate the first record, 22 Nov 2006 at TLV (Sweden), from the most recent, 1 Oct 2025 at CONITEC (Brazil).
PHARMAC (New Zealand) changed its position: restricted on 12 Nov 2009, not recommended by 5 Nov 2015.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 2 of 17 records date from 2023 or later.
6 distinct indication wordings are recorded for sunitinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 17 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess sunitinib, on 22 Nov 2006; CONITEC (Brazil) did not open a file until 1 Oct 2025 — an unusually long tail of 18.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
6 of the 9 agencies here assessed sunitinib more than once, CONITEC (Brazil) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for sunitinib.
The full ledger for sunitinib reads 9 recommended, 3 other, 2 restricted and 2 superseded, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 24 Apr 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| NYE METODER (Norway) | 13 Feb 2021 | Adjuvant behandling til kirurgi hos pasienter med høy risiko for residiv av nyrecellekarsinom | decision recorded | source |
| PHARMAC (New Zealand) | 5 Nov 2015 | Pancreatic neuroendocrine tumour | PTAC advice: Decline · decision reached | source |
| PBAC (Australia) | 2015 | Pancreatic neuroendocrine tumours | Stage IV clear cell renal cell carcinoma | Gastrointestinal stromal tumours | The PBAC recommended the listing of 37.5 mg capsule sunitinib (as malate) for the treatmen… | source |
| AWMSG (Wales) | 13 Oct 2011 | Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression … | superseded (full) | source |
12 further decisions for sunitinib, across 7 agencies, are not shown here. They include the most recent record on file, 1 Oct 2025 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 10 further source documents.
Related molecules
- cabozantinib — divergent outcome (recommended vs not recommended) on a shared indication
- tivozanib — divergent outcome (recommended vs restricted) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 17 decisions for sunitinib from 9 agencies, 2006 to 2025. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.